Back Bay Life Science Advisors published in STAT News

“The question of how to best develop and commercialize novel antibiotics while at the same time creating a return for investors remains just as puzzling as the most recalcitrant bacteria,” according to an article written by Back Bay’s Peter Bak.

Published in STAT News, “What’s holding pharma back from the next antibiotic breakthrough?” looks at hurdles holding back investors considering an anti-infective opportunity, and balances with a discussion of incentives and economic models to reduce clinical development time and costs and ensure viable reimbursement.

Dr. Bak and the Back Bay team have extensive experience in anti-infective development. Read and share the article at STAT News article here.

Comments are closed.